Blend Labs, Inc.
Business
Blend Labs, Inc. provides a cloud-based digital origination platform that streamlines end-to-end consumer banking journeys for lenders and deposit providers. It offers a suite of products including mortgage, home equity, vehicle, personal loan, credit card and deposit account workflows, add-ons like Close and Title, verification and decisioning components, Blend Builder low-code tools, and open APIs and ecosystem integrations. The company operates two reportable segments: Blend Platform (software and modular components) and Title (title, escrow, closing and settlement services). It serves financial services firms across the United States via SaaS agreements, direct sales, and integrations into digital, branch, and contact center channels.
Summary from filing dated 2025-03-13
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 124 | 116 | 110 | 235 | 234 | |
| Total cost of revenue | 32 | 33 | 33 | 146 | 119 | |
| Gross profit | 91 | 83 | 76 | 90 | 116 | |
| Research and development | 33 | 46 | 81 | 138 | 92 | |
| Sales and marketing | 29 | 34 | 57 | 85 | 84 | |
| General and administrative | 50 | 46 | 61 | 139 | 129 | |
| Restructuring | 871,000 | 6 | 20 | 15 | 0 | |
| Total operating expenses | 113 | 132 | 220 | 836 | 313 | |
| Loss from operations | −22 | −49 | −144 | −746 | −197 | |
| Interest expense | 0 | −7 | −31 | −25 | — | |
| Other income (expense), net | 21 | 13 | 7 | 5 | 493,000 | |
| Loss before income taxes | −878,000 | −43 | −167 | −766 | −208 | |
| Income tax expense | −249,000 | −109,000 | −94,000 | 2 | 39 | |
| Loss from continuing operations | −1 | −43 | −167 | — | — | |
| Loss from discontinued operations (Note 16) | −6 | −659,000 | −12 | — | — | |
| Net loss | −7 | −43 | −180 | −764 | −169 | |
| Less: Net loss attributable to noncontrolling interest included in discontinued operations | 182,000 | 74,000 | 1 | — | — | |
| Net loss attributable to Blend Labs, Inc. | −7 | −43 | −179 | −720 | −170 | |
| Less: Accretion of redeemable noncontrolling interest to redemption value from discontinued operations | −1 | −6 | −7 | — | — | |
| Less: Accretion of Series A redeemable convertible preferred stock to redemption value | −18 | −11 | 0 | 0 | −1 | |
| Net loss attributable to Blend Labs, Inc. common stockholders, basic | −26 | −60 | −185 | −769 | −171 | |
| Net loss attributable to Blend Labs, Inc. common stockholders, diluted | −26 | −60 | −185 | −769 | −171 | |
| Continuing operations, basic (in dollars per share) | −0.07 | −0.21 | −0.69 | — | — | |
| Continuing operations, diluted (in dollars per share) | −0.07 | −0.21 | −0.69 | — | — | |
| Discontinuing operations, basic (in dollars per share) | −0.03 | −0.03 | −0.07 | — | — | |
| Discontinuing operations, diluted (in dollars per share) | −0.03 | −0.03 | −0.07 | — | — | |
| Net loss per share attributable to Blend Labs, Inc. common stockholders, basic (in dollars per share) | −0.1 | −0.24 | −0.76 | −3.28 | −1.3 | |
| Net loss per share attributable to Blend Labs, Inc. common stockholders, diluted (in dollars per share) | −0.1 | −0.24 | −0.76 | −3.28 | −1.3 | |
| Basic (in shares) | 259 | 254 | 245 | 234 | 132 | |
| Diluted (in shares) | 259 | 254 | 245 | 234 | 132 | |
| Unrealized (loss) gain on marketable securities | −100,000 | 87,000 | 1 | −135,000 | −794,000 | |
| Foreign currency translation gain | 95,000 | 74,000 | 119,000 | 235,000 | −9,000 | |
| Comprehensive loss | −7 | −43 | −179 | −764 | −170 | |
| Less: Comprehensive loss attributable to noncontrolling interest included in discontinued operations | 182,000 | 74,000 | 1 | 44 | −771,000 | |
| Comprehensive loss attributable to Blend Labs, Inc. | −7 | −43 | −178 | −720 | −171 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-09-30 | FY 2025 2025-06-30 | FY 2025 2025-03-31 | FY 2024 2024-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 44 | 55 | 36 | 56 | 38 | |
| Marketable securities and other investments | 25 | 22 | 52 | 49 | 56 | |
| Trade and other receivables, net of allowance for credit losses of $112 and $50, respectively | 9 | 12 | 15 | 11 | 15 | |
| Prepaid expenses and other current assets | 15 | 20 | 17 | 15 | 17 | |
| Current assets held for sale from discontinued operations | 6 | 6 | 6 | 9 | 10 | |
| Total current assets | 98 | 116 | 126 | 139 | 135 | |
| Property and equipment, net | 23 | 22 | 21 | 17 | 12 | |
| Operating lease right-of-use assets | 1 | 2 | 2 | 262,000 | 339,000 | |
| Deferred contract costs | 3 | 3 | 3 | 3 | 3 | |
| Other non-current assets | 41 | 43 | 26 | 22 | 22 | |
| Non-current assets held for sale from discontinued operations | 3 | 3 | 4 | 6 | 6 | |
| Total assets | 170 | 189 | 182 | 187 | 178 | |
| Accounts payable | 2 | 772,000 | 1 | 3 | 2 | |
| Deferred revenue | 19 | 25 | 32 | 33 | 19 | |
| Accrued compensation | 5 | 5 | 3 | 4 | 3 | |
| Other current liabilities | 9 | 9 | 10 | 11 | 10 | |
| Current liabilities held for sale from discontinued operations | 5 | 6 | 6 | 7 | 5 | |
| Total current liabilities | 39 | 46 | 52 | 58 | 39 | |
| Other non-current liabilities | 1 | 1 | 2 | 291,000 | 278,000 | |
| Non-current liabilities held for sale from discontinued operations | 154,000 | 160,000 | 858,000 | 903,000 | 1 | |
| Total liabilities | 41 | 47 | 55 | 59 | 40 | |
| Commitments and contingencies (Note 7) | — | — | — | — | — | |
| Redeemable noncontrolling interest - held for sale from discontinued operations | 0 | — | — | — | 52 | |
| Series A redeemable convertible preferred stock, par value $0.00001 per share: 200,000 shares authorized as of December 31, 2025 and 2024, 150 shares issued and outstanding as of December 31, 2025 and 2024, respectively (Note 9) | 159 | — | — | — | 142 | |
| Class A, Class B and Class C Common Stock, par value $0.00001 per share: 3,000,000 (Class A 1,800,000, Class B 600,000, Class C 600,000) shares authorized as of December 31, 2025 and 2024; 256043436 (Class A 252,787, Class B 3,256, Class C 0) and 258172720 (Class A 254426485, Class B 3,747, Class C 0) shares issued and outstanding as of December 31, 2025 and 2024, respectively | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | |
| Additional paid-in capital | 1,361 | 1,375 | 1,378 | 1,377 | 1,328 | |
| Accumulated other comprehensive income | 597,000 | 555,000 | 514,000 | 565,000 | 602,000 | |
| Accumulated deficit | −1,392 | −1,389 | −1,401 | −1,394 | −1,385 | |
| Total stockholders equity | −30 | −13 | −23 | −17 | −56 | |
| Total liabilities, redeemable equity and stockholders equity | 170 | 189 | 182 | 187 | 178 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 29 | 28 | 46 | 110 | 71 | |
| Depreciation and amortization | 3 | 1 | 2 | 11 | 11 | |
| Amortization of deferred contract costs | 2 | 1 | 3 | 5 | 5 | |
| Amortization of debt discount and issuance costs | 0 | 690,000 | 3 | 3 | 1 | |
| Amortization of operating lease right-of-use assets | 531,000 | 2 | 3 | 4 | 3 | |
| Accelerated amortization of right-of-use asset in connection with lease abandonment | 0 | 3 | 0 | 0 | — | |
| Gain on conversion of note receivable to investment in equity securities | −825,000 | 0 | 0 | — | — | |
| Gain on investment in equity securities | −17 | −4 | 0 | −3 | 0 | |
| Loss on extinguishment of debt | 0 | 6 | 4 | 0 | 0 | |
| Gain on sale of insurance business | 0 | −9 | 0 | 0 | — | |
| Other | −312,000 | −2 | −5 | 2 | 3 | |
| Trade and other receivables | 6 | 5 | 765,000 | 12 | −6 | |
| Prepaid expenses and other assets, current and non-current | −5 | −432,000 | 2 | 9 | −14 | |
| Deferred contract costs, non-current | −557,000 | −415,000 | −762,000 | 2 | 1 | |
| Accounts payable | 206,000 | −291,000 | 1 | −5 | 2 | |
| Deferred revenue | −627,000 | 10 | 289,000 | 627,000 | −6 | |
| Accrued compensation | 807,000 | −2 | −2 | −8 | 6 | |
| Operating lease liabilities | −3 | −3 | −4 | −4 | −3 | |
| Other liabilities, current and non-current | 1 | −303,000 | −2 | −12 | 7 | |
| Net cash provided by (used in) operating activities - continuing operations | 14 | −8 | −117 | — | — | |
| Net cash used in operating activities - discontinued operations | −3 | −5 | −11 | — | — | |
| Net cash provided by (used in) operating activities | 12 | −13 | −128 | −190 | −128 | |
| Purchases of marketable securities | −35 | −102 | −236 | −146 | −352 | |
| Sale of available-for-sale securities | 21 | 100 | 56 | 6,000 | 0 | |
| Maturities of marketable securities | 47 | 53 | 310 | 247 | 125 | |
| Additions to property, equipment and internal-use software development costs | −12 | −10 | −35,000 | −2 | −2 | |
| Proceeds from sale of insurance business | 0 | 9 | 0 | 0 | — | |
| Cash received in connection with conversion of note receivable to investment in equity securities | 2 | 0 | 0 | — | — | |
| Investment in non-marketable equity securities | −4 | 0 | 0 | 0 | −3 | |
| Investment in note receivable | 0 | −5 | −3 | 0 | −3 | |
| Other | 0 | −283,000 | 0 | 0 | — | |
| Net cash provided by investing activities - continuing operations | 19 | 45 | 128 | — | — | |
| Net cash used in investing activities - discontinued operations | −195,000 | −103,000 | −552,000 | — | — | |
| Net cash provided by investing activities | 19 | 45 | 127 | 99 | −634 | |
| Proceeds from exercises of stock options, including early exercises, net of repurchases | 2 | 2 | 268,000 | 3 | 25 | |
| Taxes paid related to net share settlement of equity awards | −9 | −18 | −6 | 0 | 0 | |
| Share repurchases | −25 | 0 | 0 | — | — | |
| Repayment of long-term debt | 0 | −145 | −85 | 0 | 0 | |
| Net proceeds from the issuance of the Series A redeemable convertible preferred stock and the Haveli Warrant | 0 | 149 | 0 | 0 | — | |
| Payment for issuance costs related to the Series A redeemable convertible preferred stock and the Haveli Warrant | 0 | −9 | 0 | 0 | — | |
| Net cash used in financing activities - continuing operations | −33 | −21 | −91 | 2 | 934 | |
| Effect of exchange rates on cash, cash equivalents, and restricted cash | 0 | −5,000 | −31,000 | −116,000 | −9,000 | |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | −3 | 11 | −91 | −89 | 172 | |
| Total income taxes paid, net | 389,000 | 76,000 | 107,000 | — | — | |
| Cash paid for interest | 0 | 6 | 28 | 25 | 6 | |
| Conversion of note receivable to investment in equity securities | 10 | 0 | 0 | — | — | |
| Vesting of early exercised stock options | 0 | 363,000 | 1 | 4 | 5 | |
| Operating lease liabilities arising from obtaining new or modified right-of-use assets | 2 | 1 | 327,000 | 605,000 | 2 | |
| Stock-based compensation included in capitalized internal-use software development costs | 3 | 3 | 0 | 0 | — | |
| Covered Warrant received in connection with strategic partnership and sale of insurance business | 0 | 222,000 | 0 | 0 | — | |
| Capitalized internal-use software development costs included in accrued compensation | 129,000 | 155,000 | 0 | 0 | 0 |